R&D realignment prompts Roche to dump Transgene HPV pact

Roche has decided to exit its pact to develop and commercialize TG4001 (RG3484), a therapeutic vaccine to treat high grade cervical intraepithelial neoplasia lesions caused by human papillomavirus infection. The product is currently in a Phase IIb clinical trial. Transgene will regain full rights to the drug this summer. In a release, Transgene stressed that Roche canceled the pact not due to poor data, but because the deal no longer makes strategic sense for the Swiss drugmaker. Story